Jpmorgan Chase & CO Rubius Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.14 - $0.31 $498 - $1,103	-3,561 Reduced 61.86%	2,196 $0
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $253,511 - $710,934	-551,112 Reduced 98.97%	5,757 $2,000
Q2 2022 Aug 11, 2022	SELL	$0.79 - $5.98 $1.98 Million - $15 Million	-2,507,630 Reduced 81.83%	556,869 $474,000
Q1 2022 May 11, 2022	SELL	$4.25 - $10.4 $412,322 - $1.01 Million	-97,017 Reduced 3.07%	3,064,499 $16.9 Million
Q4 2021 Feb 10, 2022	BUY	$9.68 - $17.74 $6.86 Million - $12.6 Million	708,647 Added 28.89%	3,161,516 $30.6 Million
Q3 2021 Nov 12, 2021	BUY	$17.6 - $25.91 $43.2 Million - $63.6 Million	2,452,869 New	2,452,869 $43.9 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.